Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Halil, Yıldız"'
Publikováno v:
Kybernetes.
PurposeThis research aims to analyze the factors affecting the people's performance working in the health sector to improve the services the health sector provide to society and increase the efficiency of their institutions.Design/methodology/approac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29fae1ca22e453fe8f50e1d5b7b5cf44
https://doi.org/10.1108/k-01-2022-0011
https://doi.org/10.1108/k-01-2022-0011
Autor:
Tuncay, Güzel, Adem, Aktan, Raif, Kılıç, Bayram, Arslan, Baran, Arık, Merve, Yentür, Halil, Yıldız, Lokman, Argun, Kamran, İldırımlı, Bünyamin, Yıldırım, Muhammed, Demir, Mehmet, Özbek, Faruk, Ertaş
Publikováno v:
Anatolian journal of cardiology. 26(7)
The aim of this study was to investigate the frequency of oral anticoagulant drugs and time in therapeutic range in patients receiving warfarin in addition to the epi-demiological trial of non-valvular atrial fibrillation previously conducted in Turk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e939afc8d13f65b915e20d8c81a504b
https://pubmed.ncbi.nlm.nih.gov/35791713
https://pubmed.ncbi.nlm.nih.gov/35791713
Autor:
Burhan Aslan, Abdurrahman Akyüz, Ferhat Işık, Bedrettin Boyraz, Ümit İnci, Halil Yıldız, Murat Çap, Mehmet Zülküf Karahan, Eşref Araç, Metin Okşul, İlyas Kaya
Publikováno v:
Pacing and clinical electrophysiology : PACEREFERENCES. 45(3)
Empagliflozin is a selective SGLT2 inhibitor and provides a significant reduction in hospitalizations in heart failure patients and a reduction in combined cardiovascular deaths regardless of diabetes. The mechanisms of favorable effects remain uncle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::407417b1e25b7d21a204e6b13986ee40
https://pubmed.ncbi.nlm.nih.gov/35175628
https://pubmed.ncbi.nlm.nih.gov/35175628
Autor:
Medet Akçay, Ercan Taştan, Önder Bilge, Muhammed Demir, Halil Akın, Ümit İnci, Halil Yıldız, Mehmet Özbek, Burhan Aslan, Ferhat Işık, Eşref Araç
Objective: In recent years, sodium-glucose cotransporter-2 (SGLT-2) inhibitors are known to improve symptoms and reduce mortality in patients with heart failure (HF). Empagliflozin is an antidiabetic drug that SGLT-2 inhibitor. Empagliflozin has bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b433d363e2e733d2ce537197ce3c703
https://doi.org/10.21203/rs.3.rs-986178/v1
https://doi.org/10.21203/rs.3.rs-986178/v1
